Change search
ReferencesLink to record
Permanent link

Direct link
BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients
Lund University, Sweden; Skåne University Hospital, Sweden.
Lund University, Sweden.
Lund University, Sweden.
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Heart and Medicine Center, Department of Nephrology.
2015 (English)In: JOURNAL OF IMMUNOLOGY RESEARCH, ISSN 2314-8861, Vol. 2015, 8- p., 947934Article in journal (Refereed) Published
Abstract [en]

Patients with cystic fibrosis (CF) colonized with Pseudomonas aeruginosa (P. aeruginosa) have worse prognosis compared with patients who are not. BPI-ANCA is an anti-neutrophil cytoplasmic antibody against BPI (bactericidal/permeability increasing protein) correlating with P. aeruginosa colonization and adverse long time prognosis. Whether it provides additional information as compared to standard anti-P. aeruginosa serology tests is not known. 117 nontransplanted CF patients at the CF centre in Lund, Sweden, were followed prospectively for ten years. Bacterial colonisation was classified according to the Leeds criteria. IgA BPI-ANCA was compared with assays for antibodies against alkaline protease (AP), Elastase (ELA), and Exotoxin A (ExoA). Lung function and patient outcome, alive, lung transplanted, or dead, were registered. BPI-ANCA showed the highest correlation with lung function impairment with an r-value of 0.44. Forty-eight of the 117 patients were chronically colonized with P. aeruginosa. Twenty of these patients experienced an adverse outcome. Receiver operator curve (ROC) analysis revealed that this could be predicted by BPI-ANCA (AUC = 0.77), (p = 0.002) to a better degree compared with serology tests. BPI-ANCA correlates better with lung function impairment and long time prognosis than anti-P. aeruginosa serology and has similar ability to identify patients with chronic P. aeruginosa.

Place, publisher, year, edition, pages
Hindawi Publishing Corporation , 2015. Vol. 2015, 8- p., 947934
National Category
Rheumatology and Autoimmunity
URN: urn:nbn:se:liu:diva-120890DOI: 10.1155/2015/947934ISI: 000359240700001PubMedID: 26273683OAI: diva2:849324

Funding Agencies|Bengt Andreasson Foundation; Heart and Lung Association in Sweden

Available from: 2015-08-28 Created: 2015-08-28 Last updated: 2015-09-17

Open Access in DiVA

fulltext(1484 kB)52 downloads
File information
File name FULLTEXT01.pdfFile size 1484 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Segelmark, Mårten
By organisation
Division of Drug ResearchFaculty of Medicine and Health SciencesDepartment of Nephrology
Rheumatology and Autoimmunity

Search outside of DiVA

GoogleGoogle Scholar
Total: 52 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 44 hits
ReferencesLink to record
Permanent link

Direct link